But this has long been my opinion, as well -- so. . . I'll reprint a part of it, right here:
. . . ."Bristol-Myers Squibb has the most advanced immunotherapy. It will probably be placed in most lines of treatment if it works. A first-line treatment in combination with chemo, combined with targeted agents for patients with mutations and they will also be used as single agents when everything else has failed. Nivolumab will be the first to really change the panorama of non-small cell lung cancer treatment. . . ."
[Even so,] "I think that the best companies with the best knowledge in oncology can make huge mistakes. So I really don't think Merck's lesser grounding in the oncology area will put it at a disadvantage. They just have to equip themselves with a good advisory board and to be intelligent in the way they formulate their clinical trials. . . ."
Do stay tuned. Soon we should know that BMS has a complete jacket at FDA -- in melanoma.
No comments:
Post a Comment